Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | SURPASS ET: P1101 in essential thrombocythemia

Harinder Gill, MBBS, MD, FRCP, FRCPath, The University of Hong Kong, Hong Kong, China, describes the trial design of the Phase III randomized, open-label SURPASS ET trial (NCT04285086) assessing P1101, a next generation monopegylated interferon (IFN), in patients with high-risk essential thrombocythemia (ET). Approximately 130 patients intolerant or refractory to hydroxyurea were recruited and were either given P1101 or anagrelide. Primary endpoints include hematological responses, with secondary endpoints being allele burden measurements. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.